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optimal surveillance for other cancers is currently unclear 
and should ideally be performed as part of a clinical trial.
Conclusions Identifying a TP53 mutation in a gene panel 
test is a challenging result for the patient and clinician due to 
the high risk of second primaries and the lack of consensus 
aboutsurveillance.
Keywords TP53 · Gene panel testing · Li–Fraumeni 
syndrome
Introduction
Breast cancer gene panel testing has become widely avail-
able for women who have been diagnosed with breast cancer 
and for unaffected women who are concerned about a strong 
family history of breast cancer. Mutations in the BRCA1 
and BRCA2 genes remain by far the most common genetic 
explanation for a strong family history of breast cancer. Ger-
mline mutations in TP53 may cause an even higher risk of 
breast cancer, but these are much rarer than BRCA1/BRCA2 
mutations.
The TP53 gene is a crucial tumour suppressor gene which 
has been called ‘the guardian of the genome’. The cellular 
tumour antigen p53 protein acts as a checkpoint control fol-
lowing DNA damage. It either activates downstream genes 
to repair the damage or initiates apoptosis. Somatic muta-
tions in TP53 occur very commonly in the formation of 
many cancer types and were found in 42% of samples from 
12 different cancer types in the Pan-Cancer cohort [1], mak-
ing it the most frequently mutated gene.
Germline mutations in the TP53 gene cause a familial 
cancer predisposition. The syndrome was first observed in 
1969 by Li and Fraumeni who described four families of 
children with soft tissue sarcomas [2]. Mutation carriers 
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years old have a germline TP53 gene mutation.  Breast can-
cers in women with TP53 mutations are more likely to be 
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who have breast cancer so that adjuvant breast radiotherapy 
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have a very high lifetime risk of malignancy and the com-
monest cancers are soft tissue sarcomas and breast cancer in 
women. Depending on the pattern of cancers in a family, it 
may be described as having Li–Fraumeni Syndrome (LFS) 
(OMIM 151623), Li–Fraumeni-like syndrome (LFL) or it 
may not meet the diagnostic criteria for these. Various sets of 
diagnostic criteria and testing criteria have been developed 
(see table).
Classic Li–Fraumeni syndrome 
[3]
All of the following
 Proband with sarcoma diagnosed 
before age 45 years
 A first-degree relative with any 
cancer before 45 years
 A first or second-degree relative 
with any cancer before 45 years 
or a sarcoma at any age
Li–Fraumeni-like syndrome—
Birch [4]
All of the following
 Proband with any childhood can-
cer, or a sarcoma, brain tumour 
or ACC with onset < 45 years
 A first or second-degree relative 
with a core LFS cancer (sar-
coma, breast cancer, brain 
tumour, ACC or leukaemia) with 
onset at any age
 A first or second-degree relative 
with any cancer before age 
60 years
Li–Fraumeni-like syndrome—
Eeles [5]
Two first-degree or second-degree 
relatives with core LFS malig-
nancies (sarcoma, premenopau-
sal breast cancer, brain tumour 
ACC, leukaemia, lung [bron-
choalveolar] cancer) at any age
Revised Chompret criteria [6] Proband with a cancer belonging 
to the Li–Fraumeni spectrum 
before age 46 AND at least one 
first- or second-degree rela-
tive with a LFS tumour (except 
breast cancer if proband has 
breast cancer) before age 56 or 
with multiple tumours
OR
Proband with multiple tumours, 
two of which belong to LFS 
spectrum and first before age 
46 years
OR
Proband with adrenocortical carci-
noma or choroid plexus tumour, 
regardless of family history
Prevalence of mutations
General population
The frequency of germline pathogenic variants in TP53 in 
the general population is unknown and has been estimated 
using penetrance figures. The estimates vary between 1 
in 5000 [7] and 1 in 20,000 [8]. Gonzalez and colleagues 
estimated the frequency of TP53 germline mutations in the 
general population using the frequency of specific cancers 
(breast cancer age ≤ 30 years and adrenocortical carcinoma) 
in the general population and the frequency of that cancer 
being due to TP53 germline mutations. This gave an esti-
mated frequency of 1 in 17,000 to 1 in 23,000 people. A 
recent study of germline variation in cancer-susceptibility 
genes in a healthy cohort found 15 TP53 missense vari-
ants and did not find any nonsense or frameshift variant in 
681 individuals [9]; one missense variant was likely patho-
genic and the others were variants of unknown clinical 
significance.
Prevalence of mutations in women with early onset 
breast cancer
The prevalence of TP53 mutations among women with early 
onset breast cancer has been studied in various populations 
[10, 11]. McCuaig et al. estimated that 5–8% of women with 
breast cancer diagnosed under age 30 years and no patho-
genic variant in BRCA1 or BRCA2 will have a pathogenic 
variant in TP53, and a smaller proportion of women with 
breast cancer diagnosed aged 30–39 years [12]. The likeli-
hood of having a TP53 mutation is increased if there is a 
family history of LFS-related cancers, or a personal history 
of an additional LFS-related cancer.
In a series of patients who had a germline TP53 muta-
tion ascertained due to having a young onset cancer, it was 
estimated that 7–20% of the mutations were de novo [13]. 
This is in contrast to hereditary breast and ovarian cancer 
syndrome due to BRCA1 or BRCA2 gene mutations, where 
de novo mutations are exceedingly rare. This observation 
supports testing very young onset breast cancer patients for 
TP53, even in the absence of family history.
Prevalence of TP53 mutations in women who have 
breast cancer gene panel testing
The prevalence of TP53 mutations among women who have 
had panel testing is low at under 1% in four recent studies. 
Buys et al. found 61 women with TP53 mutations among 
35,409 women with breast cancer who had testing using a 
panel of 25 cancer genes (0.17%) [14]. Moran et al. detected 
one TP53 mutation among 190 breast cancer patients with a 
strong family history and previous negative BRCA1/BRCA2 
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testing using a protein truncation test (0.53%) [15]. Kapoor 
et al. found one TP53 mutation among 377 women who were 
offered gene testing by breast surgeons using multigene pan-
els (5–43 genes, average 14.7) (0.27%) [16]. Susswein et al. 
reported results for over 10,000 consecutive cases referred 
for evaluation of germline cancer genes. They reported nine 
pathogenic and one likely pathogenic TP53 mutation among 
3315 women with breast cancer who had not had previous 
BRCA1/BRCA2 testing (0.30%), and three pathogenic and 
one likely pathogenic TP53 mutation among 1894 women 
with breast cancer who had previous BRCA1/BRCA2 testing 
(0.21%) [17].
Founder mutations
There is a high prevalence of the c.1010G  >  A, 
p.(Arg337His) mutation in exon 10 (often referred to as 
R337H) in Southeast and Southern Brazil [18]. Individuals 
with this mutation have a similar lifetime cancer prevalence 
to other LFS carriers (about 90%) but a lower penetrance 
at young ages (< 20% at age 30 years, compared to 50% in 
other LFS carriers) [19]. It has been suggested that women 
affected with breast cancer under the age of 45 years in 
Southeast and Southern Brazil should be offered testing 
for this mutation, irrespective of family history [20]. The 
R337H mutation is not common among women diagnosed 
with breast cancer in Portugal [21]. We are not aware of any 
other founder mutations in the TP53 gene.
Penetrance of breast cancer
The penetrance of breast cancer in women with TP53 muta-
tions is very high with a cumulative incidence of 85% by 
age 60 years in the National Cancer Institute Li–Fraumeni 
Syndrome cohort [22]. The annual hazard for female breast 
cancer started to increase in the late teens and peaked at 
approximately 40 years. This was a highly selected cohort 
of 286 individuals from 107 families. Most met the criteria 
for LFS (43%) or Li–Fraumeni-like syndrome (38%). 8% had 
≥ 3 primaries and 10% had tested positive for a TP53 muta-
tion without meeting any of the current diagnostic criteria 
or testing guidelines. Another study found that the median 
age of onset of breast cancer was 34 years [23]. The lifetime 
risks in individuals without a strong family history might 
be lower.
Range of cancer sites implicated
The overall lifetime risk of cancer in individuals with 
TP53 mutations is very high. Wu et al. estimated that the 
cancer-free survival probabilities for female TP53 muta-
tion carriers were 65.2, 33.0 and 2.9% at ages 30, 45 and 
60 years, respectively. The corresponding cancer-free sur-
vival rates for male carriers were 83.4, 62.5 and 22.2% [24]. 
This gender difference is primarily the result of the high 
incidence of breast cancer among women with LFS.
There are a wide variety of cancer sites implicated in 
LFS. LFS was originally described in the families of chil-
dren with soft tissue sarcomas [2], the second commonest 
cancer diagnosis (after breast cancer) in the National Can-
cer Institute Li–Fraumeni Syndrome cohort [22]. The ‘core’ 
cancers described were sarcomas, breast cancer, adrenocorti-
cal cancers and brain tumours. In a cohort of 525 patients 
tested, 9/9 patients with choroid plexus tumours had an iden-
tifiable TP53 mutation [8]. Other cancers become commoner 
in older TP53 mutation carriers, such as lung, colorectal and 
prostate cancer. Leukaemias and lymphomas can also occur 
but are not cardinal features.
There is a high risk for multiple primary cancers and a 
study of 200 individuals from 24 LFS families found that 
15% of individuals developed a second cancer, 4% had a 
third cancer and 2% had a fourth. The cumulative probabil-
ity of a second cancer occurrence at 30 years after the first 
cancer was estimated as 75% (± 10%) [25].
Ruijs and colleagues provide estimates for the relative 
risk of different cancer types in LFS [26]. They found that 
the highest relative risks were for bone cancers (RR 107, 
95% confidence intervals 49–203), connective tissue cancers 
(RR 61, CI 33–102) and brain tumours (RR 35, CI 19–60). 
The relative risk for breast cancer was 6.4 (95% confidence 
intervals 4.3–9.3).
Determining the pathogenicity of variants
The TP53 gene is located on chromosome 17p13.1 and 
encodes the cellular tumour antigen p53. The gene has 11 
exons and is 20 kb in genomic length. The coding region 
encompasses exons 2–11 while exon 1 is non-coding and 
contains two transcriptional start sites. The majority of 
pathogenic variants are missense variants (73% in the study 
by Olivier and colleagues [23]) or small 1–4 bp deletions 
[23]. There are mutational hot spots at codons 133, 175, 
213, 220, 245, 248, 273, 282 and 337 [27]. These codons are 
also mutational hotspots in sporadic tumours. Many of these 
are within exons 5–8 which encode the core DNA-binding 
region of the gene.
95% of mutations can be detected by sequence analysis 
of all exons [28]. Only approximately 1% of mutations are 
deletions or duplications involving the coding region, exon 
1 or the promoter [28]. A functional assay may be useful 
in determining the clinical significance of novel pathogenic 
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missense variants but this is only performed in certain 
research laboratories.
There are several databases with curated information on 
TP53 variants, including the p53 Mutation in Human Can-
cer (http://p53.free.fr/) and the IARC TP53 Database (http://
p53.iarc.fr). A recent paper by Bouaoun [27] used the IARC 
database to provide an update on TP53-inherited variants, 
including those that should be considered as neutral frequent 
variants.
Genotype–phenotype correlations
There have been several studies looking at genotype–phe-
notype correlations in families with LFS and LFS-like syn-
drome. Birch and colleagues’ study of 34 families (20 LFS 
and 14 LFL) showed that individuals with missense muta-
tions in the DNA-binding region had higher overall rates of 
cancer with significantly higher rates of breast cancer and 
central nervous system tumours compared to individuals 
with missense mutations in other parts of the gene or pro-
tein-truncating mutations [29]. A study by Olivier et al. ana-
lysed the IARC database (including 1068 individuals from 
265 families) and found that missense mutations outside the 
DNA-binding region are more commonly associated with 
adrenocortical carcinoma compared to missense mutations 
in the DNA-binding domain. They also noted that individu-
als with missense mutations in the DNA-binding domain 
were more likely to have early onset breast cancer compared 
to those with missense mutations outside the DNA-binding 
domain (32 years vs. 42 years) and that mutations leading 
to a TP53 null phenotype are associated with earlier onset 
brain tumours [23].
Management implications
Management of risk of breast cancer
The option for risk-reducing bilateral mastectomy or breast 
screening should be considered in women without cancer 
with a mutation in the TP53 gene. In the UK, annual MRI 
breast screening is recommended from age 20 to 49 years 
and should be considered between 50 and 69 years. Mam-
mography is not recommended [30]. In the USA, National 
Comprehensive Cancer Network guidelines recommend 
annual breast MRI 20–29 years and annual MRI and mam-
mography from 30 to 75 years [31]. In Australia, national 
guidelines recommend that bilateral mastectomy should 
be offered, otherwise annual breast MRI is recommended 
from 20 to 50 years [32]. Based on the finding that breast 
cancer risk increases significantly after the second decade 
[22], bilateral mastectomy should be considered from age 
20 (in line with NCCN guidelines [31]).The annual breast 
cancer risk peaks at around age 40–45 and then decreases 
[22]. Bilateral mastectomy is less likely to benefit women 
over 60 years.
Management of breast cancer
Mastectomy rather than lumpectomy is recommended to 
reduce the risks of a second primary breast cancer and to 
avoid radiotherapy where possible. Bilateral mastectomy 
should also be considered due to the risk of a contralateral 
breast cancer. Contralateral breast cancer risk will depend 
on the patient’s age, but there are no clear figures from the 
literature.
There are concerns about increased risk of radiation-
induced second primary tumours. Heymann et al. [33] 
describe a series of 8 patients with germline TP53 muta-
tions who were treated for breast cancer between 1997 and 
2007 from 47 documented Li–Fraumeni families; three 
underwent conservative breast surgery with post-operative 
radiotherapy, three had mastectomy and radiotherapy and 
two had mastectomy with no radiotherapy. Among the six 
who received radiotherapy, there were three ipsilateral 
breast recurrences, three contralateral breast cancers, two 
radio-induced cancers (one breast histiocytoma fibrosar-
coma and one chest wall angiosarcoma) and three new pri-
maries (including one papillary thyroid carcinoma which 
developed inside the radiation field after 2 years). One 
contralateral breast cancer occurred in the two patients 
who did not have radiotherapy, with a median follow-up 
of 6 years. Despite the small sample size, this study does 
suggest that radiotherapy should be avoided or used with 
extreme caution in TP53 mutation carriers after very care-
ful consideration of the risks and benefits.
A study of the breast cancer histopathology in TP53 
carriers showed that most invasive ductal carcinomas and 
ductal carcinomas in situ (DCIS) in LFS are hormone 
receptor positive and/or HER-2 positive [34]. In this study, 
there were 32 invasive ductal carcinomas in 30 women 
with confirmed germline TP53 mutations. 84% of the 
tumours stained positive for oestrogen receptors, 72% for 
progesterone receptors and 63% showed HER-2 amplifica-
tion and/or overexpression. Melhem-Bertrandt et al. [35] 
have also reported that women who are TP53 mutation 
carriers are more likely to have HER2 amplification and/
or overexpression (present in 67% of cases and 25% of 
controls in this study).
These histopathological findings have management 
implications as treatment is more likely to include Tras-
tuzumab (Herceptin) and hormone therapy. There are no 
published data on treatment response to chemotherapeu-
tic agents so standard chemotherapy regiments should be 
used.
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Management of risks of other cancers
There is no international consensus about the best surveil-
lance for TP53 mutation carriers. In the UK, breast MRI 
screening is the only recommendation. In the USA, annual 
complete physical examination including neurologic and 
skin examination is recommended, and 2–5 yearly colonos-
copy from age 25 [31]. In the Netherlands, annual breast 
surveillance from age 20 to 25 and an optional annual physi-
cal examination is recommended [36]. The Australian guide-
lines recommend annual clinical review, and to consider 2–5 
yearly colonoscopy from 25 years if there is a family history 
of colorectal cancer, or 2–5 yearly endoscopy if there is a 
family history of gastric cancer [32].
An intensive and comprehensive surveillance programme 
has been proposed by Villani et al. for children and adults 
who carry a TP53 germline mutation [37]. This uses mul-
tiple modalities (physical examination, blood tests, ultra-
sound, mammography, MRI and colonoscopy). The results 
of a non-randomised trial showed good long-term compli-
ance with the protocol. It reported a significantly improved 
five-year overall survival in the surveillance group. How-
ever, there was a very high rate of symptomatic tumours in 
the group who initially declined surveillance. A larger-scale 
randomised controlled trial is required to evaluate the pro-
tocol further.
Neonatal testing for the c.1010G > A, p.(Arg337His) 
mutation and subsequent surveillance for adrenocortical 
tumours in mutation carriers has been evaluated in a large, 
non-randomised clinical trial in Southern Brazil [38]. Adren-
ocortical tumours diagnosed in the surveillance group were 
smaller and had an improved clinical outcome. Although the 
results are not directly transferrable to other populations of 
TP53 carriers with different mutations, it does suggest that 
surveillance for adrenocortical tumours in children should 
be considered.
The UK SIGNIFY study [39] investigated the role of one-
off whole body non-contrast MRI screening in asymptomatic 
TP53 mutation carriers. Four malignancies were diagnosed 
among 44 TP53 mutation carriers and none in matched con-
trols. Two malignancies were not picked up on scan—one 
patient developed leukaemia and one became symptomatic 
from a mediastinal liposarcoma which was thought to be 
a pericardial cyst on scan. The difference between cancer 
detection in carriers and controls was not statistically sig-
nificant, but the trend of the results suggests that whole body 
MRI is a useful investigation.
Ongoing clinical trials
There are several ongoing trials using whole body MRI 
screening (reviewed in McBride 2014 [40] and Ballinger 
2015 [41]). The LIFSCREEN trial [42] at the Institut 
Gustave Roussy (Villejuif, France) is a randomised trial with 
annual whole body MRI screening for three years in the 
intervention arm and standard care in the control arm. It is 
recruiting individuals with TP53 mutations (age 5–71 years). 
The Surveillance of Multi-Organ Cancer Prone Syndrome 
(SMOC) trial [43] in Australia is enrolling individuals with 
a germline mutation in a cancer risk gene (including TP53) 
and those at 50% risk aged 18–70 years for a period of 
3 years. It is a non-randomised trial using annual physical 
examination, full blood count, whole body MRI, breast MRI, 
ultrasound and mammography (in females) with additional 
procedures of gastroscopy and colonoscopy based on family 
history. The Dana Faber Cancer Institute whole body MRI 
study involves annual physical examination and whole body 
MRI and is currently recruiting children only.
Based on the observation that metformin has been asso-
ciated with reduced cancer risk in several epidemiological 
studies [44], a pilot study for chemoprevention using met-
formin has been commenced which assesses the safety and 
tolerability of the drug over 14 weeks, measuring IGF-1, 
insulin and IGFBP3 levels in blood at baseline, and weeks 0 
and 8 [45].
As the optimal screening for other cancers in TP53 muta-
tion carriers remains unclear, screening should ideally be 
undertaken as part of clinical trial.
Example
A fifty-year old unaffected woman with no family history 
has a TP53 pathogenic variant detected on panel testing. The 
evidence is that this scenario will be very unusual, so we 
would advise reviewing the literature about the pathogenic-
ity of the specific variant, and we would consider repeating 
the test (in case of a sample error). We would advise that 
she is at high risk of developing breast cancer, although she 
has ‘lived through’ a substantial part of that risk. We would 
advise annual MRI breast screening or bilateral mastectomy. 
We would also consider a baseline whole body MRI, based 
on the UK SIGNIFY study results.
Support groups
Some women may require additional psychological sup-
port. There are several patient support groups including the 
Li–Fraumeni Syndrome Association <http://www.lfsasso-
ciation.org> based in the USA, and the George Pantziarka 
TP53 Trust <http://www.tp53.co.uk> based in the UK.
Conclusions
Finding a germline TP53 mutation in a woman with breast 
cancer has significant clinical implications for the patient 
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and her family. Mastectomy is preferred in the treatment of 
breast cancer so that radiotherapy can be avoided or mini-
mised. Risk-reducing contralateral mastectomy should also 
be considered, otherwise MRI breast screening should be 
initiated. The risk of developing second or third primary 
malignancies is high, and optimal surveillance is currently 
unclear. Where possible, screening should be undertaken as 
part of a clinical trial.
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